Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 3/2012

01-03-2012 | Contrast Media

Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study

Authors: O. Dahlqvist Leinhard, N. Dahlström, J. Kihlberg, P. Sandström, T. B. Brismar, Ö. Smedby, P. Lundberg

Published in: European Radiology | Issue 3/2012

Login to get access

Abstract

Objectives

To develop and evaluate a procedure for quantifying the hepatocyte-specific uptake of Gd-BOPTA and Gd-EOB-DTPA using dynamic contrast-enhanced (DCE) MRI.

Methods

Ten healthy volunteers were prospectively recruited and 21 patients with suspected hepatobiliary disease were retrospectively evaluated. All subjects were examined with DCE-MRI using 0.025 mmol/kg of Gd-EOB-DTPA. The healthy volunteers underwent an additional examination using 0.05 mmol/kg of Gd-BOPTA. The signal intensities (SI) of liver and spleen parenchyma were obtained from unenhanced and enhanced acquisitions. Using pharmacokinetic models of the liver and spleen, and an SI rescaling procedure, a hepatic uptake rate, K Hep, estimate was derived. The K Hep values for Gd-EOB-DTPA were then studied in relation to those for Gd-BOPTA and to a clinical classification of the patient’s hepatobiliary dysfunction.

Results

K Hep estimated using Gd-EOB-DTPA showed a significant Pearson correlation with K Hep estimated using Gd-BOPTA (r = 0.64; P < 0.05) in healthy subjects. Patients with impaired hepatobiliary function had significantly lower K Hep than patients with normal hepatobiliary function (K Hep = 0.09 ± 0.05 min-1 versus K Hep = 0.24 ± 0.10 min−1; P < 0.01).

Conclusions

A new procedure for quantifying the hepatocyte-specific uptake of T 1-enhancing contrast agent was demonstrated and used to show that impaired hepatobiliary function severely influences the hepatic uptake of Gd-EOB-DTPA.

Key Points

• The liver uptake of contrast agents may be measured with standard clinical MRI.
• Calculation of liver contrast agent uptake is improved by considering splenic uptake.
• Liver function affects the uptake of the liver-specific contrast agent Gd-EOB-DTPA.
• Hepatic uptake of two contrast agents (Gd-EOB-DTPA, Gd-BOPTA) is correlated in healthy individuals.
• This method can be useful for determining liver function, e.g. before hepatic surgery
Literature
1.
Tsuda N, Okada M, Murakami T (2010) New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 73:137–142PubMedCrossRef
2.
Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, Gex-Fabry M (2005) Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Invest Radiol 40(11):705–714PubMedCrossRef
3.
Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6(5):282–291PubMedCrossRef
4.
Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42(4):242–247. doi:10.​1097/​01.​rli.​0000258058.​44876.​a5 PubMedCrossRef
5.
6.
Motosugi U, Ichikawa T, Sou H et al (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30(5):1042–1046. doi:10.​1002/​jmri.​21956 PubMedCrossRef
7.
8.
9.
10.
Treier R, Steingoetter A, Fried M, Schwizer W, Boesiger P (2007) Optimized and combined T1 and B1 mapping technique for fast and accurate T1 quantification in contrast-enhanced abdominal MRI. Magn Reson Med 57(3):568–576. doi:10.​1002/​mrm.​21177 PubMedCrossRef
11.
Huang W, Wang Y, Panicek DM, Schwartz LH, Koutcher JA (2009) Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. Magn Reson Imaging 27(6):852–858. doi:10.​1016/​j.​mri.​2009.​01.​020 PubMedCrossRef
12.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649PubMedCrossRef
13.
Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33(2):464–470PubMedCrossRef
14.
15.
Ernst RR, Anderson WA (1966) Application of fourier transform spectroscopy to magnetic resonance. Review of Scientific Instruments 37(1):93–102CrossRef
16.
17.
18.
19.
Thomsen C, Christoffersen P, Henriksen O, Juhl E (1990) Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study. Magn Reson Imaging 8(5):599–604PubMedCrossRef
20.
Van Lom KJ, Brown JJ, Perman WH, Sandstrom JC, Lee JK (1991) Liver imaging at 1.5 tesla: pulse sequence optimization based on improved measurement of tissue relaxation times. Magn Reson Imaging 9(2):165–171PubMedCrossRef
21.
22.
Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195(3):785–792PubMed
23.
24.
Lee MS, Lee JY, Kim SH et al (2011) Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI. J Magn Reson Imaging 33(1):149–159. doi:10.​1002/​jmri.​22429 PubMedCrossRef
Metadata
Title
Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study
Authors
O. Dahlqvist Leinhard
N. Dahlström
J. Kihlberg
P. Sandström
T. B. Brismar
Ö. Smedby
P. Lundberg
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
European Radiology / Issue 3/2012
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-011-2302-4

Other articles of this Issue 3/2012

European Radiology 3/2012 Go to the issue

Neuro

Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement

Chest

Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria

Chest

Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH)

Head and Neck

Functional MR imaging of the Eustachian tube in patients with clinically proven dysfunction: correlation with lesions detected on MR images

Contrast Media

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine

Experimental

Systematic review: Bias in imaging studies - the effect of manipulating clinical context, recall bias and reporting intensity